Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 401–500 of 2,576
Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini, L., Racchi, M., Binetti, G., Trabucchi, M., Solerte, S. B., Alkon, D., Etcheberrigaray, R., Gibson, G., Blass, J., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 175
Qiu, W. Q., Ye, Z., Kholodenko, D., Seubert, P., & Selkoe, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.10.6641 · Cited by 177
Self-citationAmyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?
Sun, X., Steffens, D. C., Au, R., Folstein, M., Summergrad, P., Yee, J., Rosenberg, I., Mwamburi, D. M., & Qiu, W. Q. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.5.542 · Cited by 174
Dementia of the Alzheimer Type
Jalbert, J. J., Daiello, L. A., & Lapane, K. L. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn008 · Cited by 174
Bowen, R. L., Verdile, G., Liu, T., Parlow, A. F., Perry, G., Smith, M. A., Martins, R. N., & Atwood, C. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m311993200 · Cited by 174
Kragh, P. M., Nielsen, A. L., Li, J., Du, Y., Lin, L., Schmidt, M., Bøgh, I. B., Holm, I. E., Jakobsen, J. E., Johansen, M. G., et al. (2009) · Transgenic Research · doi:10.1007/s11248-009-9245-4 · Cited by 174
“This process can be accelerated if the level of Ab42 is increased, which has been shown by co-expression of mutant human PSEN1 (Borchelt et al. 1997).”
BackgroundPET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 174
Giannakopoulos, P., Hof, P. R., Michel, J.-P., Guimon, J., & Bouras, C. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(97)00023-4 · Cited by 175
Identification of a novel family of presenilin homologues
Ponting, C. P. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1037 · Cited by 174
Weidemann, A., Paliga, K., Dürrwang, U., Reinhard, F. B. M., Schuckert, O., Evin, G., & Masters, C. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.9.5823 · Cited by 172
Stable Association of Presenilin Derivatives and Absence of Presenilin Interactions with APP
Thinakaran, G., Regard, J. B., Bouton, C. M. L., Harris, C. L., Price, D. L., Borchelt, D. R., & Sisodia, S. S. (1998) · Neurobiology of Disease · doi:10.1006/nbdi.1998.0171 · Cited by 175
“…PS variants influence APP processing in a manner that elevates production of highly amyloidogenic, 42- to 43-aminoacid b-amyloid peptides (Ab42) (Scheuner et al., 1996; Duff et al., 1996; Borchelt et al., 1996; Citron et al., 1997; Tomita et al., 1997), which are deposited early and selectively…”
Backgroundγ-secretases: from cell biology to therapeutic strategies
Bergmans, B. A., & De Strooper, B. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70332-1 · Cited by 170
Mattson, M. P., Zhu, H., Yu, J., & Kindy, M. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01358.2000 · Cited by 172
The genes associated with early-onset Alzheimer’s disease
Dai, M.-H., Zheng, H., Zeng, L.-D., & Zhang, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.23738 · Cited by 167
Biogenesis and metabolism of Alzheimer’s disease Aβ amyloid peptides
Evin, G., & Weidemann, A. (2002) · Peptides · doi:10.1016/s0196-9781(02)00063-3 · Cited by 170
TREM2 in CNS homeostasis and neurodegenerative disease
Painter, M. M., Atagi, Y., Liu, C.-C., Rademakers, R., Xu, H., Fryer, J. D., & Bu, G. (2015) · Molecular Neurodegeneration · doi:10.1186/s13024-015-0040-9 · Cited by 169
“tations found in patients with familial EOAD—APP, or PSEN1 and PSEN2, components of the γ-secretase complex—result in overproduction of amyloidogenic Aβ [50].”
BackgroundA High-Throughput Screen for Compounds That Inhibit Aggregation of the Alzheimer’s Peptide
Kim, W., Kim, Y., Min, J., Kim, D. J., Chang, Y.-T., & Hecht, M. H. (2006) · ACS Chemical Biology · doi:10.1021/cb600135w · Cited by 169
“) Second, detection of compounds with low activity is important because drugs with modest effects on aggregation may in fact be sufficient to treat AD: In early onset AD caused by familial mutations in APP or in the presenilins, levels of A 42 are increased by as little as 30% (3).”
BackgroundQian, S., Jiang, P., Guan, X.-M., Singh, G., Trumbauer, M. E., Yu, H., Chen, H. Y., Van der Ploeg, L. H. T., & Zheng, H. (1998) · Neuron · doi:10.1016/s0896-6273(00)80999-x · Cited by 169
Light and Electron Microscopic Localization of Presenilin-1 in Primate Brain
Lah, J. J., Heilman, C. J., Nash, N. R., Rees, H. D., Yi, H., Counts, S. E., & Levey, A. I. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-06-01971.1997 · Cited by 168
“These indications of a role for PS1 in intracellular transport are even more intriguing when considered in light of reports that mutations in the presenilins affect the processing and secretion of Ab peptide (Martins et al., 1995; Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996).”
BackgroundGenetically Engineered Pig Models for Human Diseases
Prather, R. S., Lorson, M., Ross, J. W., Whyte, J. J., & Walters, E. (2013) · Annual Review of Animal Biosciences · doi:10.1146/annurev-animal-031412-103715 · Cited by 170
Current status on Alzheimer disease molecular genetics: from past, to present, to future
Bettens, K., Sleegers, K., & Van Broeckhoven, C. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq142 · Cited by 169
Biochemical markers related to Alzheimer’s dementia in serum and cerebrospinal fluid
Teunissen, C. E., de Vente, J., Steinbusch, H. W. M., & De Bruijn, C. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00328-1 · Cited by 166
The amyloid precursor protein of Alzheimer’s disease and the Aβ peptide
Storey, & Cappai (1999) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.1999.00164.x · Cited by 169
Evidence for a physical interaction between presenilin and Notch
Ray, W. J., Yao, M., Nowotny, P., Mumm, J., Zhang, W., Wu, J. Y., Kopan, R., & Goate, A. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3263 · Cited by 170
Mark, R. J., Keller, J. N., Kruman, I., & Mattson, M. P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00196-0 · Cited by 167
Zhu, H., Guo, Q., & Mattson, M. P. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01827-2 · Cited by 168
Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., & Kosenko, E. A. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.09.005 · Cited by 165
“Likewise, the mechanism by which presenilin (PSEN1, PSEN2) missense mutations alter γ-secretase-mediated cleavage to increase the ratio of Aβ1–42 to Aβ1–40 is an important concern due to the highly pathogenic nature of Aβ1–42 (Scheuner et al., 1996).”
BackgroundCalcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions
Thibault, O., Porter, N. M., Chen, K.-C., Blalock, E. M., Kaminker, P. G., Clodfelter, G. V., Brewer, L. D., & Landfield, P. W. (1998) · Cell Calcium · doi:10.1016/s0143-4160(98)90064-1 · Cited by 167
The γ-secretase complex: from structure to function
Zhang, X., Li, Y., Xu, H., & Zhang, Y.-W. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00427 · Cited by 160
“directly linked to APP processing and are all seen to increase the relative abundance of the more aggregation-prone Aβ42 compared to Aβ40 (Borchelt et al., 1996, 1997; Duff et al., 1996; Scheuner et al., 1996; Citron et al., 1997; Siman et al., 2000; Flood et al., 2002; Haass et al., 2012).”
BackgroundAlzheimer disease therapy: Can the amyloid cascade be halted?
Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17527 · Cited by 164
The presenilin genes: a new gene family involved in Alzheimer disease pathology
Cruts, M., Hendriks, L., & Van Broeckhoven, C. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.supplement_1.1449 · Cited by 163
Teixeira, A. L., Barbosa, I. G., Diniz, B. S., & Kummer, A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.111 · Cited by 163
Monsonego, A., Maron, R., Zota, V., Selkoe, D. J., & Weiner, H. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191118298 · Cited by 161
Self-citationIntramembrane proteolysis by presenilins
Steiner, H., & Haass, C. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35043065 · Cited by 161
“This was shown originally in primary cells derived from carriers of presenilin mutation”
BackgroundUpdate on the Pharmacological Treatment of Alzheimers Disease
Massoud, F., & Gauthier, S. (2010) · Current Neuropharmacology · doi:10.2174/157015910790909520 · Cited by 163
“All mutations described in the rare autosomal-dominant forms of AD affect APP and γ-secretase and are associated with increased deposition of Aβ [3, 75, 83, 107].”
BackgroundLazarov, V. K., Fraering, P. C., Ye, W., Wolfe, M. S., Selkoe, D. J., & Li, H. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602321103 · Cited by 161
Self-citationThal, D. R., Holzer, M., Rüb, U., Waldmann, G., Günzel, S., Zedlick, D., & Schober, R. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7380 · Cited by 162
Liang, Y., Lin, S., Beyer, T. P., Zhang, Y., Wu, X., Bales, K. R., DeMattos, R. B., May, P. C., Li, S. D., Jiang, X., et al. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02183.x · Cited by 160
“Mutations in the amyloid precursor protein (APP) gene linked to autosomal dominant early onset AD have all been shown to predictably alter Ab synthesis (Scheuner et al. 1996; Hardy and Selkoe 2002).”
BackgroundGrimm, M. O. W., Mett, J., Stahlmann, C. P., Haupenthal, V. J., Zimmer, V. C., & Hartmann, T. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00098 · Cited by 159
“Less than 5% of all AD cases are genetically based (familial AD, FAD) due to mutations in the genes encoding for APP or presenilin1 (PS1) and presenilin2 (PS2), proteins involved in the proteolytic cleavage of APP, leading to an earlier age of onset (Scheuner et al., 1996; Hardy, 1997).”
BackgroundAmyloid β-peptide polymerization studied using fluorescence correlation spectroscopy
Tjernberg, L. O., Pramanik, A., Björling, S., Thyberg, P., Thyberg, J., Nordstedt, C., Berndt, K. D., Terenius, L., & Rigler, R. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80020-9 · Cited by 160
Carlson, G. A., Borchelt, D. R., Dake, A., Turner, S., Danielson, V., Coffin, J. D., Eckman, C., Meiners, J., Nilsen, S. P., Younkin, S. G., et al. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.11.1951 · Cited by 158
“Methods for preparing brain and quantifying Aβ have been described previously (13, 18 ).”
BackgroundMethodSelf-citationAlzheimer's disease and post-operative cognitive dysfunction
Xie, Z., & Tanzi, R. E. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.01.014 · Cited by 159
Self-citationGenetics of Alzheimer's Disease
Guerreiro, R., & Hardy, J. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0295-9 · Cited by 155
“In contrast, the majority (90%) of plasma samples from late-onset ‘sporadic’ AD cases did not show an increase in A 42(43), which suggests that the increase in the presenilin and APP families is a consequence of the mutations and not an indirect consequence of the disease state [35].”
BackgroundResultInfluentialSelf-citationAntioxidant Therapy in Alzheimers Disease: Theory and Practice
Aliev, G., Obrenovich, M., Reddy, V., Shenk, J., Moreira, P., Nunomura, A., Zhu, X., Smith, M., & Perry, G. (2008) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955708786369582 · Cited by 159
“In AD, it is thought that mutations in these proteins are associated with AD by affecting the processing of A PP [59].”
BackgroundIncreased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain
. Swatton, J. E., Sellers, L. A., Faull, R. L. M., Holland, A., Iritani, S., & Bahn, S. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03365.x · Cited by 159
Scheinfeld, M. H., Roncarati, R., Vito, P., Lopez, P. A., Abdallah, M., & D'Adamio, L. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108357200 · Cited by 159
Pathological and physiological functions of presenilins
Vetrivel, K. S., Zhang, Y.-W., Xu, H., & Thinakaran, G. (2006) · Molecular Neurodegeneration · doi:10.1186/1750-1326-1-4 · Cited by 156
“FAD-linked mutations in PS intriguingly influence γ-secretase cleavage by an elusive mechanism that modulates the proteolysis of APP to selectively enhance the generation of highly amyloidogenic Aβ42 peptides [5, 6 ].”
InfluentialA Molecular Switch in Amyloid Assembly: Met35and Amyloid β-Protein Oligomerization
Bitan, G., Tarus, B., Vollers, S. S., Lashuel, H. A., Condron, M. M., Straub, J. E., & Teplow, D. B. (2003) · Journal of the American Chemical Society · doi:10.1021/ja0349296 · Cited by 161
Guénette, S. Y., Chen, J., Jondro, P. D., & Tanzi, R. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10832 · Cited by 158
Self-citationBinding of the Molecular Chaperone αB-Crystallin to Aβ Amyloid Fibrils Inhibits Fibril Elongation
Shammas, S. L., Waudby, C. A., Wang, S., Buell, A. K., Knowles, T. P. J., Ecroyd, H., Welland, M. E., Carver, J. A., Dobson, C. M., & Meehan, S. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2011.07.056 · Cited by 156
Low-Density Lipoprotein Receptor Family
Bu, G., Li, Y., & Cam, J. (2001) · Molecular Neurobiology · doi:10.1385/mn:23:1:53 · Cited by 137
Begley, J. G., Duan, W., Chan, S., Duff, K., & Mattson, M. P. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721030.x · Cited by 158
“…the amyloid precursor protein (APP) such that production of a neurotoxic form of Ab (Ab1–42) is increased (Borchelt et al., 1996; Duff et al., 1996; Scheuner et al., 1996; Weidemann et al., 1997; Xia et al., 1997), whereas levels of a neuroprotective secreted form of APP are decreased (Ancolio et…”
BackgroundCedazo-Mínguez, Á., & Winblad, B. G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.09.008 · Cited by 183
“Plasma total Ab or Ab-42 are increased in cases of familial AD (Kosaka et al., 1997; Scheuner et al., 1996) and in Downs syndrome with amyloid precursor protein (APP) triplication (Schupf et al., 2001) but the results were not consistent with the diagnosis of sporadic AD (Assini et al., 2004;…”
BackgroundResultPassive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 155
Presenilin-1 mutations in Alzheimer's disease
Russo, C., Schettini, G., Saido, T. C., Hulette, C., Lippa, C., Lannfelt, L., Ghetti, B., Gambetti, P., Tabaton, M., & Teller, J. K. (2000) · Nature · doi:10.1038/35014735 · Cited by 158
Self-citationMurphy, M. P., Hickman, L. J., Eckman, C. B., Uljon, S. N., Wang, R., & Golde, T. E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11914 · Cited by 157
Self-citationAssembly, Trafficking and Function of γ-Secretase
Kaether, C., Haass, C., & Steiner, H. (2006) · Neurodegenerative Diseases · doi:10.1159/000095267 · Cited by 129
Functional and morphological impact of ER stress on mitochondria
Vannuvel, K., Renard, P., Raes, M., & Arnould, T. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24360 · Cited by 154
“Moreover, mutations in presenilin 1 and presenilin 2 also cause familial AD and are associated with increased Ab plaques (Borchelt et al., 1996; Scheuner et al., 1996).”
BackgroundA Hexameric Peptide Barrel as Building Block of Amyloid‐β Protofibrils
Lendel, C., Bjerring, M., Dubnovitsky, A. P., Kelly, R. T., Filippov, A. V., Antzutkin, O. N., Nielsen, N. C., & Härd, T. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201406357 · Cited by 166
Presenilins and Alzheimer’s disease: biological functions and pathogenic mechanisms
Czech, C., Tremp, G., & Pradier, L. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00033-7 · Cited by 158
Loss of Neprilysin Function Promotes Amyloid Plaque Formation and Causes Cerebral Amyloid Angiopathy
Farris, W., Schütz, S. G., Cirrito, J. R., Shankar, G. M., Sun, X., George, A., Leissring, M. A., Walsh, D. M., Qiu, W. Q., Holtzman, D. M., et al. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070105 · Cited by 177
Self-citationZou, K., Kim, D., Kakio, A., Byun, K., Gong, J., Kim, J., Kim, M., Sawamura, N., Nishimoto, S., Matsuzaki, K., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02018.x · Cited by 155
“Familial-AD-linked mutations of b-amyloid precursor protein (APP) and presenilins increase the relative concentration of Ab1–42 (Suzuki et al. 1994; Borchelt et al. 1996; Scheuner et al. 1996; Citron et al. 1997; Eckman et al. 1997; Tomita et al. 1997).”
BackgroundPotential role of presenilin-regulated signaling pathways in sporadic neurodegeneration
Koo, E. H., & Kopan, R. (2004) · Nature Medicine · doi:10.1038/nm1065 · Cited by 170
Ward, R. V., JENNINGS, K. H., Jepras, R., Neville, W. A., OWEN, D. E., HAWKINS, J., Christie, G., Davis, J. B., George, A. R., Karran, E. H., et al. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3480137 · Cited by 153
Miners, J. S., Van Helmond, Z., Chalmers, K., Wilcock, G., Love, S., & Kehoe, P. G. (2006) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000240463.87886.9a · Cited by 154
Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer’s disease
Robinson, S. R., & Bishop, G. M. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00342-6 · Cited by 173
Presenilins Are Processed by Caspase-type Proteases
Loetscher, H., Deuschle, U., Brockhaus, M., Reinhardt, D., Nelboeck, P., Mous, J., Grünberg, J., Haass, C., & Jacobsen, H. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.33.20655 · Cited by 155
Direct association of presenilin‐1 with β‐catenin
Murayama, M., Tanaka, S., Palacino, J., Murayama, O., Honda, T., Sun, X., Yasutake, K., Nihonmatsu, N., Wolozin, B., & Takashima, A. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00886-2 · Cited by 156
Lannfelt, L., Möller, C., Basun, H., Osswald, G., Sehlin, D., Satlin, A., Logovinsky, V., & Gellerfors, P. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt246 · Cited by 153
“other genes in families with autosomal dominant, earlyonset AD [5-9].”
BackgroundSelf-citationLagomarsino, V. N., Pearse, R. V., Liu, L., Hsieh, Y.-C., Fernandez, M. A., Vinton, E. A., Paull, D., Felsky, D., Tasaki, S., Gaiteri, C., et al. (2021) · Neuron · doi:10.1016/j.neuron.2021.08.003 · Cited by 151
Self-citationCaenorhabditis elegans as a model system for human diseases
Markaki, M., & Tavernarakis, N. (2020) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2019.12.011 · Cited by 177
Zhu, Y. J., Lin, H., & Lal, R. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.9.1244 · Cited by 152
Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum
Schneider, P., Hampel, H., & Buerger, K. (2009) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00104.x · Cited by 152
“However, most groups investigating Aβ plasma levels found no significant differences between AD and control cases [12,13,15– 17].”
BackgroundKelliher, M., Fastbom, J., Cowburn, R. F., Bonkale, W., Ohm, T. G., Ravid, R., Sorrentino, V., & O'Neill, C. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00042-1 · Cited by 129
Nontoxic Amyloid β Peptide1-42 Suppresses Acetylcholine Synthesis
Hoshi, M., Takashima, A., Murayama, M., Yasutake, K., Yoshida, N., Ishiguro, K., Hoshino, T., & Imahori, K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.4.2038 · Cited by 150
Berezovska, O., Lleo, A., Herl, L. D., Frosch, M. P., Stern, E. A., Bacskai, B. J., & Hyman, B. T. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.0364-05.2005 · Cited by 151
“All mutations increase the A 42 /A 40 ratio and lead to early-onset autosomal dominantly inherited AD (Borchelt et al., 1996; Scheuner et al., 1996).”
Evidence for a Six-transmembrane Domain Structure of Presenilin 1
Lehmann, S., Chiesa, R., & Harris, D. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.18.12047 · Cited by 152
Landman, N., Jeong, S. Y., Shin, S. Y., Voronov, S. V., Serban, G., Kang, M. S., Park, M. K., Di Paolo, G., Chung, S., & Kim, T.-W. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604954103 · Cited by 149
Defining Molecular Targets to Prevent Alzheimer Disease
Selkoe, D. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.2.192 · Cited by 149
“In cell culture, transgenic mouse models, and the sera and brains of affected patients, it has been shown that PS1 and PS2 missense mutations increase the production of A 42, the highly selfaggregating 42-residue form of A , often at the expense of the more commonly produced 40-residue form.(11) The mutations do so be…”
BackgroundSelf-citationElevated plasma amyloid β-peptide 1–42 and onset of dementia in adults with Down syndrome
Schupf, N., Patel, B. N., Silverman, W. P., Zigman, W. B., Zhong, N., Tycko, B., Mehta, P. D., & Mayeux, R. P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)01657-3 · Cited by 161
Molecular genetics of Alzheimer's disease
Cruts, M., & vanBroeckhoven, C. (1998) · Annals of Medicine · doi:10.3109/07853899809002605 · Cited by 148
Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains
Welander, H., Frånberg, J., Graff, C., Sundström, E., Winblad, B., & Tjernberg, L. O. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06170.x · Cited by 148
“The majority of these mutations are associated with increased production of Ab or an increased Ab42/Ab40 ratio (Scheuner et al. 1996; Wolfe 2007).”
BackgroundHwang, D. Y., Chae, K. R., Kang, T. S., Hwang, J. H., Lim, C. H., Kang, H. K., Goo, J. S., Lee, M. R., Lim, H. J., Min, S. H., et al. (2002) · The FASEB Journal · doi:10.1096/fj.01-0732com · Cited by 147
Raimondi, I., Izzo, L., Tunesi, M., Comar, M., Albani, D., & Giordano, C. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00435 · Cited by 155
“Its hallmarks are intracellular neurofibrillary tangles (Arriagada et al., 1992; Reitz et al., 2011) and extracellular senile plaques mainly composed of β-amyloid (Aβ) (Scheuner et al., 1996; Shankar et al., 2008).”
BackgroundLanz, T. A., Himes, C. S., Pallante, G., Adams, L., Yamazaki, S., Amore, B., & Merchant, K. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.048280 · Cited by 160
“There have been two reports of an increase in A levels in the plasma of AD patients (Matsubara et al., 1999; Mayeux et al., 1999), but several others show no change (Ida et al., 1996; Scheuner et al., 1996; Tamaoka et al., 1996; Mehta et al., 2000).”
BackgroundSecretase inhibitors and modulators for Alzheimer’s disease treatment
Tomita, T. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.24 · Cited by 146
THE GENETICS AND MOLECULAR PATHOLOGY OF ALZHEIMER'S DISEASE
Selkoe, D. J. (2000) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70232-2 · Cited by 163
Self-citationChromosome Missegregation and Trisomy 21 Mosaicism in Alzheimer's Disease
Geller, L. N., & Potter, H. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0236 · Cited by 149
Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice
Schuessel, K., Schäfer, S., Bayer, T. A., Czech, C., Pradier, L., Müller-Spahn, F., Müller, W. E., & Eckert, A. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.09.003 · Cited by 146
Plaques, Tangles, and Memory Loss in Mouse Models of Neurodegeneration
Eriksen, J. L., & Janus, C. G. (2007) · Behavior Genetics · doi:10.1007/s10519-006-9118-z · Cited by 146
Haass, C., & Selkoe, D. (2022) · PLOS Biology · doi:10.1371/journal.pbio.3001694 · Cited by 145
“What about the much more common AD-causing mutations in the homologous presenilin-1 (PS1) and presenilin-2 (PS2) genes? Strikingly, all these mutations increase the relative levels of the longer Aβ42 and Aβ43 species, similar to the carboxyl-terminal APP mutations (Fig 1A) [24,25].”
BackgroundSelf-citationGenomics of Alzheimer Disease: A Review
Rosenberg, R. N., Lambracht-Washington, D., Yu, G., & Xia, W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0301 · Cited by 146
Paola, D., Domenicotti, C., Nitti, M., Vitali, A., Borghi, R., Cottalasso, D., Zaccheo, D., Odetti, P. R., Strocchi, P., Marinari, U. M., et al. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2164 · Cited by 179
Perturbed Neurogenesis in the Adult Hippocampus Associated with Presenilin-1 A246E Mutation
Chevallier, N. L., Soriano, S., Kang, D. E., Masliah, E., Hu, G., & Koo, E. H. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62962-8 · Cited by 152
Evidence for phosphorylation and oligomeric assembly of presenilin 1
Seeger, M., Nordstedt, C., Petanceska, S., Kovacs, D. M., Gouras, G. K., Hahne, S., Fraser, P., Levesque, L., Czernik, A. J., George-Hyslop, P. S., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5090 · Cited by 145
Self-citationPresenilins: Genes for Life and Death
Haass, C. (1997) · Neuron · doi:10.1016/s0896-6273(00)80309-8 · Cited by 162
Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?
Swerdlow, R. H. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.06.021 · Cited by 173
“All the autosomal dominant deterinistic mutations (in the APP, presenilin 1 and presenilin 2 enes) favor processing of APP by the beta-gamma secretase leavage system, and in such a way that beta amyloid 1–42 s preferentially generated [186].”
BackgroundInfluentialPresenilin function and γ‐secretase activity
Brunkan, A. L., & Goate, A. M. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03099.x · Cited by 145
“(2005) 93, 769–792 769 (Ab42) versus 40-residue Ab (Ab40) (Ab42 : Ab40), thus defining a common AD phenotype caused by APP, PS1 and PS2 mutations (Scheuner et al. 1996).”
BackgroundTherapeutic Potential of γ -Secretase Inhibitors and Modulators
Imbimbo, B. (2008) · Current Topics in Medicinal Chemistry · doi:10.2174/156802608783334015 · Cited by 143
Acceleration of Amyloid β-Peptide Aggregation by Physiological Concentrations of Calcium
Isaacs, A. M., Senn, D. B., Yuan, M., Shine, J. P., & Yankner, B. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602061200 · Cited by 143
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.